新闻
PALI
--
0.00%
--
BRIEF-Palisade Bio Files For Offer And Resale By Selling Stockholder Of Up To 1.9 Mln Shares
reuters.com · 09/23 21:13
3 低价股内部人士正在购买
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 09/23 11:11
Palisade Bio 将出席 HC Wainwright 第 23 届年度全球投资虚拟会议
CARLSBAD, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces today that Chief Executive Officer Tom Hallam, Ph...
GlobeNewswire · 09/09 12:30
Benzinga 的最高评级升级,2021 年 8 月 31 日降级
Upgrades
Benzinga · 08/31 15:44
CRSR、XSPA 和 PALI 是上市前的赢家
AC Immune ACIU +71% after reporting mid-stage data for Alzheimer’s candidate Regional Health Properties (NYSE:RHE) +40%. Siyata Mobile  (NASDAQ:SYTA) +31%. Spok Holdings SPOK +22% on a buyout offer from Acacia Research for $10.75 per
Seekingalpha · 08/31 12:21
美信集团以买入评级启动对 Palisade Bio 的覆盖,宣布目标价为 7 美元
Maxim Group analyst Naz Rahman initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
Benzinga · 08/31 12:05
--Maxim 以 7 美元的目标价启动 Palisade Bio
MT Newswires · 08/31 07:41
简报 Palisade Bio 表示,截至 2021 年 6 月 30 日的现金和现金等价物为 1270 万美元,而未偿债务为 110 万美元
reuters.com · 08/24 12:28
Palisade Bio Q2 每股收益(4.10 美元)低于同比(0.67 美元)
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(4.10) per share. This is a 511.94 percent decrease over losses of $(0.67) per share from the same period last year.
Benzinga · 08/24 12:17
Palisade Bio 股价飙升; Co 宣布由 Yuma 区域医疗中心投资 520 万美元
Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade Bio" or the "Company"), a late‐stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announces a new
Benzinga · 08/20 13:27
Palisade Bio 宣布由 Yuma 区域医疗中心投资 520 万美元
-- $5.2M invested at $3.45 stock price
GlobeNewswire · 08/20 13:25
Palisade Bio 从尤马地区医疗中心获得 520 万美元的投资;股份预付
MT Newswires · 08/20 09:53
The Daily Biotech Pulse:AzurRx 关注数据,Agios 的 Mitapivat 监管申请获得优先审查接受,FDA 批准葛兰素史克
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse:礼来重组神经科学业务部门,Helius Medical 获得突破性指定,Ra Medical 出售皮肤科业务
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
周一触及 52 周低点的股票
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
每日生物技术脉搏:赛诺菲以 3.2B 美元的价格收购 Translate Bio,礼来的第二季度收益令人失望,Bausch 剥离医学美容业务
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2)
Benzinga · 08/03 11:55
简要栅栏生物文件通过出售股东转售多达 730 万股普通股
reuters.com · 07/30 20:37
The Daily Biotech Pulse:Erytech 进入快速通道指定,葛兰素史克 FDA 点头,Alnylam 的临床合作,4 次 IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 11:53
简报 Palisade Bio 和 Newsoara 宣布 LB1148 2 期研究的积极顶线结果
reuters.com · 07/29 15:52
微牛提供丰富的实时PALI股票新闻,让你可以通过多个平台了解PALI股票行情最新动态,这些免费的Palisade Bio Inc新闻可以帮助你做出明智投资。
PALI 简况
Palisade Bio Inc(原名:Seneca Biopharma Inc)是一家生物制药公司。该公司专注于开发疗法,以帮助患有急性和慢性胃肠道问题的患者避免术后消化酶的损害。其候选产品LB1148是可用于III期的蛋白酶抑制剂,可减少腹部粘连并有助于在手术后恢复肠道功能。它致力于开发口服产品候选物以治疗因蛋白酶(肠道消化酶)逸出肠道而引起的疾病,包括外科疾病和炎症。LB1148是一种丝氨酸蛋白酶抑制剂的口服制剂,旨在中和手术期间从肠道释放的有效消化蛋白酶的活性。